...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human vaccines >Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial
【24h】

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial

机译：含和不含磷酸铝的13价肺炎球菌结合疫苗制剂的安全性和免疫原性以及23价肺炎球菌多糖疫苗选择制剂在老年人中的比较一项随机开放标签试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AIPO_4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged >65 years (n = 105) not pre-vaccinated with PPSV23.
机译：这项随机开放标签试验旨在提供初步的免疫原性和安全性数据，以支持开发成人用的儿科13价肺炎球菌结合疫苗（PCV13）。目的是：确定适合年龄的PCV13制剂，即使用（n = 309）或不使用（n = 304）磷酸铝（AIPO_4）;比较所选的PCV13制剂（n = 309）与23价肺炎球菌多糖疫苗（PPSV23; n = 301）;并与一项扩展研究一起，评估未接种PPSV23的65岁以上成年人（n = 105）中每隔1年连续使用肺炎球菌疫苗的情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号